Danielle Bargo

443 total citations
25 papers, 257 citations indexed

About

Danielle Bargo is a scholar working on Genetics, Economics and Econometrics and Epidemiology. According to data from OpenAlex, Danielle Bargo has authored 25 papers receiving a total of 257 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 11 papers in Economics and Econometrics and 9 papers in Epidemiology. Recurrent topics in Danielle Bargo's work include Inflammatory Bowel Disease (12 papers), Microscopic Colitis (9 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). Danielle Bargo is often cited by papers focused on Inflammatory Bowel Disease (12 papers), Microscopic Colitis (9 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). Danielle Bargo collaborates with scholars based in United States, United Kingdom and Germany. Danielle Bargo's co-authors include Leonardo Salese, Joseph C. Cappelleri, Marco DiBonaventura, Alessandro Armuzzi, M. Tarallo, James Lucas, Jane Wolstenholme, Anthony Harnden, Kay Wang and Lucy Abel and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The American Journal of Gastroenterology.

In The Last Decade

Danielle Bargo

25 papers receiving 254 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Danielle Bargo United States	10	110	109	68	53	33	25	257
Ellen Maxwell Australia	11	15 0.1×	32 0.3×	29 0.4×	10 0.2×	10 0.3×	18	290
J. K. S. Nuytinck Netherlands	5	9 0.1×	53 0.5×	37 0.5×	16 0.3×	28 0.8×	6	253
Alexander S. Qian United States	10	72 0.7×	70 0.6×	94 1.4×	47 0.9×	3 0.1×	44	329
Catherine Moltzan Canada	6	45 0.4×	21 0.2×	27 0.4×	4 0.1×	22 0.7×	10	216
Waseem Khaliq United States	11	39 0.4×	31 0.3×	27 0.4×	19 0.4×	1 0.0×	51	322
Yun‐Yi Chen Taiwan	9	66 0.6×	79 0.7×	54 0.8×	15 0.3×	2 0.1×	38	296
Robyn Laube Australia	10	89 0.8×	79 0.7×	159 2.3×	8 0.2×	4 0.1×	25	352
Oluwatosin Ayeni South Africa	11	42 0.4×	98 0.9×	11 0.2×	38 0.7×	7 0.2×	36	341
Harkirat Singh India	7	162 1.5×	126 1.2×	94 1.4×	7 0.1×	3 0.1×	11	318
A.L. Frauchiger Switzerland	9	32 0.3×	53 0.5×	23 0.3×	23 0.4×	6 0.2×	13	388

Countries citing papers authored by Danielle Bargo

Since Specialization

Citations

This map shows the geographic impact of Danielle Bargo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danielle Bargo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danielle Bargo more than expected).

Fields of papers citing papers by Danielle Bargo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danielle Bargo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danielle Bargo. The network helps show where Danielle Bargo may publish in the future.

Co-authorship network of co-authors of Danielle Bargo

This figure shows the co-authorship network connecting the top 25 collaborators of Danielle Bargo. A scholar is included among the top collaborators of Danielle Bargo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danielle Bargo. Danielle Bargo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kent, Seamus, Páll Jónsson, Ivy Altomare, et al.. (2023). Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study. BMJ Open. 13(10). e074559–e074559. 4 indexed citations

Kent, Seamus, Shrujal S. Baxi, Amy L. Copeland, et al.. (2022). P14 Exploring the Potential for EHR-Derived Real-World Data to Reduce Uncertainty in HTA Decision-Making: A Case Study of Long-Term Survival Outcomes. Value in Health. 25(1). S3–S4. 1 indexed citations

Jónsson, Páll, Seamus Kent, Amy L. Copeland, et al.. (2021). PCN170 Can Early U.S. Adoption of Cancer Drugs Inform HTA Decision-Making?. Value in Health. 24. S51–S51. 1 indexed citations

Long, Millie D., Russell D. Cohen, Timothy W. Smith, et al.. (2021). Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis. Digestive Diseases. 40(5). 553–564. 8 indexed citations

Bargo, Danielle, Joseph C. Cappelleri, Marco DiBonaventura, et al.. (2021). Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. Inflammatory Intestinal Diseases. 6(4). 186–198. 7 indexed citations

Wang, Xiaoliang, Blythe Adamson, Andrew Briggs, et al.. (2021). Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer. Value in Health. 25(2). 230–237. 3 indexed citations

Armuzzi, Alessandro, M. Tarallo, James Lucas, et al.. (2020). The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterology. 20(1). 18–18. 37 indexed citations

Armuzzi, Alessandro, M. Tarallo, James Lucas, et al.. (2020). Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS ONE. 15(1). e0227914–e0227914. 33 indexed citations

Bentley, Sarah, Chloe Johnson, Elaine Brohan, et al.. (2020). Improving patient-clinician communication following nephrectomy in renal cell carcinoma: Development, content validation and pilot testing of a conversation aid tool. Patient Education and Counseling. 104(1). 99–108. 1 indexed citations

10.

Dignaß, Axel, John Waller, Joseph C. Cappelleri, et al.. (2019). Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. Journal of Medical Economics. 23(4). 415–427. 12 indexed citations

11.

Long, Millie D., Timothy W. Smith, Marco DiBonaventura, et al.. (2019). Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States. Inflammatory Bowel Diseases. 26(6). 941–948. 9 indexed citations

12.

DiBonaventura, Marco, J.C. Cappelleri, Agnes Kisser, et al.. (2019). PGI9 COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS IN GERMANY. Value in Health. 22. S617–S617. 1 indexed citations

13.

Dignaß, Axel, John Waller, J.C. Cappelleri, et al.. (2019). P782 Living with ulcerative colitis in Germany: quantifying the healthcare resource utilisation and direct healthcare costs associated with the treatment of moderate to severe ulcerative colitis in Germany. Journal of Crohn s and Colitis. 13(Supplement_1). S512–S512. 2 indexed citations

14.

Boegemann, Martin, et al.. (2018). Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry. Anticancer Research. 38(11). 6413–6422. 20 indexed citations

15.

Smith, Timothy W., et al.. (2018). Dose Escalation and Treatment Patterns of Advanced Therapies Used to Treat Ulcerative Colitis: A Retrospective Database Analysis in the United States. The American Journal of Gastroenterology. 113(Supplement). S353–S353. 3 indexed citations

16.

Wolstenholme, Jane, Danielle Bargo, Kay Wang, et al.. (2018). Preference-based measures to obtain health state utility values for use in economic evaluations with child-based populations: a review and UK-based focus group assessment of patient and parent choices. Quality of Life Research. 27(7). 1769–1780. 28 indexed citations

17.

Proskorovsky, Irina, Ágnes Benedict, Sylvie Négrier, et al.. (2018). Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses. BMC Cancer. 18(1). 1271–1271. 6 indexed citations

18.

Brown, Jacqueline, et al.. (2017). Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling. Expert Review of Pharmacoeconomics & Outcomes Research. 17(2). 153–164. 11 indexed citations

19.

Stokes, Elizabeth A, Sarah Wordsworth, Danielle Bargo, et al.. (2016). Are lower levels of red blood cell transfusion more cost-effective than liberal levels after cardiac surgery? Findings from the TITRe2 randomised controlled trial. BMJ Open. 6(8). e011311–e011311. 24 indexed citations

20.

Campbell, Helen, Elizabeth A Stokes, Danielle Bargo, et al.. (2015). Quantifying the healthcare costs of treating severely bleeding major trauma patients: a national study for England. Critical Care. 19(1). 276–276. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact